The changing landscape of treatment for acquired hemophilia A

The changing landscape of treatment for acquired hemophilia A

Acquired hemophilia A (AHA) is a rare acquired autoimmune disorder caused by autoantibodies against coagulation factor VIII (FVIII), which cause a hemorrhagic diathesis, not rarely of severe degree. Standard treatment consists of bleeding control with bypassing agents (recombinant activated factor...

Full description

Saved in:
Bibliographic Details
Main Authors: Massimo Franchini, Daniele Focosi
Format: Article
Language:English
Published: PAGEPress Publications 2025-01-01
Series:Bleeding, Thrombosis and Vascular Biology
Subjects:
Acquired Hemophilia A
FVIII inhibitor
rituximab
emicizumab
Online Access:https://www.btvb.org/btvb/article/view/157
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items